Kathleen Polson, NP

Learn how clinicians judge tumor treatment success beyond scan shrinkage, using symptoms, stable disease, and surveillance insights from desmoid tumor trials.

Learn how clinicians address fertility risks from newer cancer therapies, discuss ovarian toxicity, pregnancy avoidance, and when to refer for preservation.

Learn how clinicians proactively manage toxicities from targeted systemic cancer therapies, using early education, monitoring, and dose adjustments to maintain adherence.

Learn how clinics proactively manage oral cancer therapy toxicities—education, early follow-ups, and dose tweaks to control hand-foot, GI

Learn how tumor boards unite sarcoma experts—and how remote clinics join Zoom reviews, online panels, and fast second opinions.

Desmoid tumor care shifts from surgery to systemic options like gamma secretase inhibitors; experts weigh chemo, TKIs, and selective cryoablation or radiation.

Explore updated desmoid tumor care: NCCN-backed targeted drugs like nirentasertib, plus when cryoablation or radiation fits.

Explore how desmoid tumor genetics guide diagnosis and FAP screening, why APC testing matters, and when molecular profiling shapes monitoring decisions.

Experts unpack desmoid tumor diagnosis, watchful waiting, and when systemic therapy beats surgery, highlighting NCCN-guided multidisciplinary care.

In this opening segment, the panel discusses how patients with desmoid tumor typically present and how referral pathways have evolved in recent years.